Rafferty Asset Management
AERI

Rafferty Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Rafferty Asset Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,021
Closed -$119K – 1352
2021
Q4 		$119K Buy
+17,021
New +$178K ﹤0.01% 1249
2020
Q1 		– Sell
-13,109
Closed -$317K – 852
2019
Q4 		$317K Sell
13,109
-469
-3% -$9.71K ﹤0.01% 779
2019
Q3 		$261K Buy
+13,578
New +$311K ﹤0.01% 758

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Rafferty Asset Management's AERI Position: Q1 2022 in Review

Rafferty Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2022, closing a stake of 17,021 shares — an estimated $119K sold.

Rafferty Asset Management first reported a position in AERI in Q3 2019 and held it in 3 quarters. The position peaked at $317K in Q4 2019. 136 funds tracked by Wall St. Rank hold AERI as of Q1 2022.

  • Rafferty Asset Management reported no remaining Aerie Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 17,021 Aerie Pharmaceuticals shares in Q1 2022, an estimated $119K.
  • Rafferty Asset Management first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Rafferty Asset Management's Aerie Pharmaceuticals position peaked at $317K in Q4 2019.
  • 136 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2022.

Based on Rafferty Asset Management's 13F filing for Q1 2022, filed 13 May 2022.